TY - JOUR
T1 - Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines
AU - Saad, Ayman
AU - Loren, Alison
AU - Bolaños-Meade, Javier
AU - Chen, George
AU - Couriel, Daniel
AU - Di Stasi, Antonio
AU - El-Jawahri, Areej
AU - Elmariah, Hany
AU - Farag, Sherif
AU - Gundabolu, Krishna
AU - Gutman, Jonathan
AU - Ho, Vincent
AU - Hoeg, Rasmus
AU - Horwitz, Mitchell
AU - Hsu, Joe
AU - Kassim, Adetola
AU - Dabaja, Mohamed Kharfan
AU - Magenau, John
AU - Martin, Thomas
AU - Mielcarek, Marco
AU - Moreira, Jonathan
AU - Nakamura, Ryotaro
AU - Nieto, Yago
AU - Ninos, Cameron
AU - Oliai, Caspian
AU - Patel, Seema
AU - Randolph, Brion
AU - Schroeder, Mark
AU - Tzachanis, Dimitrios
AU - Varshavsky-Yanovsky, Asya Nina
AU - Vusirikala, Madhuri
AU - Algieri, Frankie
AU - Pluchino, Lenora A.
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2023/2
Y1 - 2023/2
N2 - The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.
AB - The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.
UR - https://www.scopus.com/pages/publications/85148114831
U2 - 10.6004/jnccn.2023.0007
DO - 10.6004/jnccn.2023.0007
M3 - Article
C2 - 36791762
AN - SCOPUS:85148114831
SN - 1540-1405
VL - 21
SP - 108
EP - 115
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 2
ER -